CRNX · NASDAQ · STOCK
Crinetics Pharmaceuticals, Inc.
$84.35
52W $27.52 – $84.38
65/100
$8.94B
-16.7
0.13
Is CRNX Bullish or Bearish?
Bullish.
Innellis AI committee rates Crinetics Pharmaceuticals, Inc. (CRNX) Buy with a composite score of 65/100
, based on 6 analysts with 50% agreement.
Last updated August 11, 2026.
What Would Change This View
- Upgrade to Strong Buy
- Requires a committee score of 75.0 — +9.65 from today. Applies on the first day at or above the line; upgrades are never dampened.
- Downgrade to Watch
- Requires the score to fall below 55.0 — -10.35 from today. The band boundary is 60.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.
Executive Summary
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull & Bear Case
Bull Case
- Revenue growing 2928.4% YoY -- genuine top-line momentum — Growth
- Price structure making higher highs and higher lows — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 4.5x prices in significant intangible value — Value
- ROE of only -44.2% -- cheap may mean cheap for a reason — Value
- RSI at 89 is in overbought territory — Technical
- MACD histogram negative -- bearish momentum — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Weekly RSI at 91 -- overbought on the larger timeframe too — Technical
Both cases are generated from quantitative data signals, not qualitative or
forward-looking judgement. They summarise what the numbers say today.
Price History (6M)
AI Investment Committee
Committee Consensus
As of August 11, 2026
Overall Committee Score
65/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 16%
of 192 Healthcare peers
Value Analyst
neutral
43
/ 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
− Price-to-book of 4.5x prices in significant intangible value
Growth Analyst
bullish
85
/ 100 · Low confidence
Strong, accelerating growth with consistent execution
+ Revenue growing 2928.4% YoY -- genuine top-line momentum
Technical Analyst
neutral
54
/ 100 · High confidence
Mixed or range-bound price action
+ Price structure making higher highs and higher lows
− RSI at 89 is in overbought territory
Risk Analyst
bullish
75
/ 100 · Moderate confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
+ Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock
Macro Analyst
bullish
78
/ 100 · Moderate confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
+ VIX regime is low -- calm backdrop supports risk-taking
News Analyst
neutral
58
/ 100 · Low confidence
News flow is mixed or quiet -- no strong signal either way right now
Portfolio Manager
neutral
55
/ 100 · Moderate confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− 2 existing position pair(s) are highly correlated already
Technical Analysis
RSI (14)
89.2
Overbought
MACD Histogram
-1.637
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Mixed
Bollinger %B
1.14
Above Upper Band
Price vs Moving Averages
EMA 9
$83.89
Above
EMA 21
$79.98
Above
EMA 50
$67.33
Above
EMA 200
$49.35
Above
Fundamental Analysis
Valuation
69
Profitability
25
Financial Health
100
Cash Flow
15
Valuation
P/E Ratio
-16.7×
P/B Ratio
7.47×
PEG Ratio
0.82
Dividend Yield
0.00%
52W High
$84.38
52W Low
$27.52
Quality & Growth
ROE
-4690.3%
ROA
-4097.9%
Gross Margin
9916.0%
Operating Margin
—
Revenue Growth YoY
—
Debt / Equity
0.00
AI Fundamental Assessment
[reduced confidence: limited earnings history] P/E ratio of -16.7 (inexpensive relative to a 15-40x range); Price-to-book of 7.5x; PEG ratio of 0.8 (under 1.0 suggests growth is undervalued relative to price); Return on equity of -46.9%; Return on assets of -41.0%; Net margin of -1189.9%; Gross margin of 99.2%; Current ratio of 15.57 (healthy short-term liquidity); Debt-to-equity of 0.00; Free cash flow per share is negative (-4.03); Earnings-history trend unavailable; growth based on TTM year-over-year only.
Get the Full CRNX Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →